azd-1446
Small moleculeexperimental
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00803855)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1ccc(Cl)o1)N1CC2CNCC2C1- Mol. weight
- 240.69 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2179529 ↗
Also known as
- 3-(5-chloro-2-furoyl)-3,7-diazabicyclo(3.3.0)octane
- azd1446
- azd1446
- azd1446
- azd1446
- azd-1446
- azd-1446
- tc-6683
- tc-6683
- tc-6683
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01199315 | Phase 1 | Sep 1, 2010 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
| NCT01125683 | Phase 2 | Jun 1, 2010 | AstraZeneca |
| NCT01092299 | Phase 1 | Feb 1, 2010 | AstraZeneca, IQVIA |
| NCT01021189 | Phase 1 | Dec 1, 2009 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
| NCT01039701 | Phase 2 | Dec 1, 2009 | AstraZeneca |
| NCT01044342 | Phase 1 | Dec 1, 2009 | AstraZeneca |
| NCT01012375 | Phase 2 | Nov 1, 2009 | AstraZeneca, University of Vermont |
| NCT00997308 | Phase 1 | Oct 1, 2009 | AstraZeneca |
| NCT00902993 | Phase 1 | Apr 1, 2009 | AstraZeneca |
| NCT00886067 | Phase 1 | Apr 1, 2009 | AstraZeneca |
| NCT00803855 | Phase 1 | Dec 1, 2008 | AstraZeneca |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 11 | 11 | 2 | 2008 |
| Kyushu Clinical Pharmacolgy Reasearch Clinic | Academic/Hospital | 2 | 0 | 1 | 2009 |
| IQVIA | For profit | 1 | 0 | 1 | 2010 |
| University of Vermont | Academic/Hospital | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1